New CEO tasked with keeping Chapel Hill medtech on track to commercialization


The public company is under new leadership as it works to advance its surgical system to clinical trials and keep its stock from being delisted.

Previous Raleigh financier claims his business partner cheated him out of millions
Next Flood gates open on metro Denver housing inventory in June